Our Synergy Brings Life to Your Science

Company Profile
Dishman Carbogen Amcis Ltd focusses on the reduction of operational risk in chemical development and commercial manufacturing by:

• Minimising the time associated with drug development
• Decreasing the risks associated with drug development
• Providing long-term and value-added contract manufacturing solutions

OUR FOCUS: CLIENT SATISFACTION

SUPPORTING THE PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRIES

We have been supporting the pharmaceutical and biopharmaceutical industries with drug development for over 30 years, assisting our clients in developing and bringing new drugs to market while improving the lives of their patients across the world.

OUR VISION

Our objective is to help our customers create a better world as the partner of choice to develop and manufacture complex and challenging substances, highly potent active ingredients, and breaking new ground with innovative vitamin, healthcare, and industrial products.

WELCOME TO DISHMAN CARBOGEN AMCIS LTD

Table of Contents

- Company Profile
- Contract Research & Manufacturing Services
- Highly Potent API Supply
- Technology Transfer – Case Studies

R&D centre at Bavla, India

We have been supporting the pharmaceutical and biopharmaceutical industries with drug development for over 30 years, assisting our clients in developing and bringing new drugs to market while improving the lives of their patients across the world.

OUR FOCUS: CLIENT SATISFACTION

Dishman Carbogen Amcis Ltd focusses on the reduction of operational risk in chemical development and commercial manufacturing by:

• Minimising the time associated with drug development
• Decreasing the risks associated with drug development
• Providing long-term and value-added contract manufacturing solutions
Dishman Carbogen Amcis Ltd is a global outsourcing partner for the pharmaceutical industry offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis Ltd improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in India.

Our commitment is to deliver high added value solutions with technical excellence and to be a reliable partner to our customers, protecting their interests as if they were our own.

Dishman Carbogen Amcis Ltd owns CARBOGEN AMCIS and form together the Dishman Carbogen Amcis Group.
Dishman Carbogen Amcis Ltd contract research and manufacturing services are the very core of our business. We offer a portfolio of services from process R&D, through kilo and pilot supply to full scale and commercial manufacture from purpose built and dedicated facilities.

By offering technical and manufacturing excellence in multiple locations around the globe, Dishman Carbogen Amcis Group is THE global outsourcing partner for the pharmaceutical industry, providing innovative development to value-for-money, long-term commercial supply.

PROCESS R&D
Dishman Carbogen Amcis Ltd offers Process R&D with a specialization in developing processes that are truly scalable through to commercialization, be this through process research, process development or optimisation.

We have 200 staff operating in continuous three shifts, 6 day R&D operations in state-of-the-art dedicated R&D centres. Our promise is safe, efficient scale-up and problem solving delivering robust, economic processes.

Dishman Carbogen Amcis Ltd enforces strict IP protection policies. We protect our customers’ interests as if they were our own.

ANALYTICAL SERVICES
Analytical services support both process control and material characterization for R&D and manufacturing operations, from initial raw material release through to the release of the final APIs. The range of our equipment is necessarily extensive, mirroring that which one would find within an integrated pharmaceutical company.

PILOT, FULL SCALE & COMMERCIAL SUPPLY
We offer an extensive range of segregated, purpose built, kilo and pilot scale facilities for cGMP production of API. These facilities are an integral part of our R&D centres to facilitate maximum interaction and ensure seamless process transfer from laboratory to plant.

At commercial scale, we offer a vast range of dedicated and multipurpose facilities for the cGMP production of APIs and intermediates.

• 12 multi-purpose and dedicated production facilities
• Comprehensive range of skills and capabilities encompassing all routine chemistries and a wide range of sophisticated, modern technologies
• USFDA inspected facilities
• Multiple site, multiple country locations, all operating to the highest international standards of quality, safety and environmental control
• >1725m³ of reactor capacity
• An ongoing commitment to add services and expertise valued by our customers.
To support the Active Pharmaceutical Ingredient (API) development process through all stages, a variety of high-containment analytical purification and milling capabilities complement the chemistry service portfolio.** HIGHLY POTENT API FOR (PRE)CLINICAL TRIALS & COMMERCIAL USE**

We offer services starting from laboratory scale for process research and development purposes, up to large-scale manufacturing on 630 L in Switzerland, on 1,600 L scale in Bavla, India and on 8,000 L scale in Shanghai, China. These facilities offer containment down to category 4 (down to 0.05 μg/m³) in Switzerland and India and down to category 3 in China (down to 1 μg/m³).

To support the Active Pharmaceutical Ingredient (API) development process through all stages, a variety of high-containment analytical purification and milling capabilities complement the chemistry service portfolio.** HIGHLY POTENT API FOR (PRE)CLINICAL TRIALS & COMMERCIAL USE**

We offer services starting from laboratory scale for process research and development purposes, up to large-scale manufacturing on 630 L in Switzerland, on 1,600 L scale in Bavla, India and on 8,000 L scale in Shanghai, China. These facilities offer containment down to category 4 (down to 0.05 μg/m³) in Switzerland and India and down to category 3 in China (down to 1 μg/m³).

**SAFETY & PRODUCT QUALITY**
We are fully committed to managing the risks associated with handling and producing highly potent and/or toxic materials. Safety and quality considerations encompass our staff, customers and patients using the materials we produce, as well as the environment and our neighbors. We are dedicated to maintaining and improving safety, environmental and health standards above and beyond the standard legal requirements. This remains the responsibility of both our management and individual employees. All processes follow our "protection cascade" of four increasing levels of containment technology systems and procedures, ensuring that worker safety and product quality are never compromised.

**PROTECTION CASCADE**
Our rigorous system of Standard Operating Procedures (SOPs) and Unit Operation Procedures (UOPs), supplemented by extensive worker training, enhances safe working processes and awareness of potent compound safety at all Dishman Carbogen Amcis Group’s production sites.

**HIGHLY POTENT API SUPPLY**

- Dishman Carbogen Amcis Group offers unparalleled capability in scale-up development and commercial manufacture for highly potent compounds. These highly potent services are offered under the CARBOGEN AMCIS business.

The Dishman Carbogen Amcis Group provides state-of-the-art containment services. All facilities operate to current Good Manufacturing Practice (cGMP) and can produce material for preclinical testing, clinical trials and commercial use. Our manufacturing sites are regularly inspected by the US Food and Drug Administration (FDA) and local regulatory bodies.

All containment facilities are designed based on a containment concept utilizing barrier isolation technology and Rapid Transfer Ports (RTPs) as well as a strict zone concept with pressure cascades, airlocks and access controls. This allows the safe handling of highly potent compounds including cytotoxics.
Dishman Carbogen Amcis Group is a global, multi-site, multi-location organization, offering our customers the opportunity to obtain a comprehensive range of chemical and manufacturing solutions from one single supplier. This extends from rapid Active Pharmaceutical Ingredients (APIs) supply for preclinical and clinical use (through CARBOGEN AMCIS) to large-scale manufacture of intermediates and APIs. An efficient technology transfer process is the key for a successful transfer either from the customer to Dishman Carbogen Amcis Ltd or among the Dishman Carbogen Amcis Group sites.

**TECHNOLOGY TRANSFER – CASE STUDIES**

**TECHNOLOGY TRANSFER PROCESS**

Complex, multi-step processes under both current Good Manufacturing Practice (cGMP) and non-GMP have been successfully transferred. For transfer outside of Switzerland, a specialist team follows an established three-stage procedure:

1. **INITIATION**: the scope and goals are agreed upon by all parties – preparation of technology transfer master plan, definition of responsibilities, as well as preparation and transfer of technical information package;

2. **PILOTING**: the process is trialed in the lab and in small production runs and extensively reviewed – compliance with regulatory and quality standards; and

3. **SIGN-OFF**: the mutually agreed process is accepted by all parties – production against established batch instructions. A crucial element in successfully transferring technology processes across linguistic and cultural barriers is frequent communication involving our experienced personnel.

Clear definitions of the responsibilities of the technology transfer team members during the transfer process minimize the time and effort needed for this critical step in the successful scale-up of intermediates or APIs. Dishman Carbogen Amcis Ltd can also offer technology transfer for our own processes which will enable our customers to produce their APIs with our technologies.

**CASE STUDY 1**: Cost Advantages and Continuous Local Management

The first three steps from a registered process, previously run in Switzerland on 1,600 L scale, were successfully transferred to operations in India within a timeframe of five months. The intermediate of an API which goes generic in a few years required us to provide larger quantities of intermediates at lower costs. The process is now being performed on a scale up to 4,000 L with the intermediate being sent to Switzerland for further conversion to the final API. This approach offers the maximum flexibility in handling the cost and quantity demands of the product in development and commercialization life cycles. The customer benefits from cost advantage and continuous local project management.

**CASE STUDY 2**: Customer dedicated facilities

A large, multinational pharmaceutical company required significant cost of goods reduction to deliver a market leading drug product. Dishman Carbogen Amcis Ltd optimized the process and built a dedicated facility for the API production. Dishman Carbogen Amcis Ltd further reduced costs by developing its own more cost-effective routes for the three key starting materials. An overall cost reduction of more than 50% was achieved. Routine commercial manufacture is now ongoing at the Bavla site, offering the customer significant cost advantages and a simplified and secure supply chain.

**CASE STUDY 3**: Commercialization from a Laboratory Process within 12 months

A European Specialty Pharmaceutical company approached Dishman Carbogen Amcis Ltd for the contract manufacture of a late-life cycle API. This client had a non-infringing laboratory scale process for the API which needed optimization and scale up to commercial production. The process was transferred and then optimized at an R&D level. This was followed by pilot scale validation batches and then 10mL commercial production within 9 months of initiating technology transfer.

During the commercial production, alternative, more cost effective supply solutions were found for key starting materials and these were incorporated into production post validation. An agreed regulatory programme was completed and Dishman Carbogen Amcis Ltd provided the client with a full technical dossier to enable regulatory filings. As a consequence of the success of this program, the client has transferred a further 3 projects into the Dishman Carbogen Amcis Group.

**TECHNOLOGY TRANSFER – CASE STUDIES**

**CASE STUDY 1**: Cost Advantages and Continuous Local Management

The first three steps from a registered process, previously run in Switzerland on 1,600 L scale, were successfully transferred to operations in India within a timeframe of five months. The intermediate of an API which goes generic in a few years required us to provide larger quantities of intermediates at lower costs. The process is now being performed on a scale up to 4,000 L with the intermediate being sent to Switzerland for further conversion to the final API. This approach offers the maximum flexibility in handling the cost and quantity demands of the product in development and commercialization life cycles. The customer benefits from cost advantage and continuous local project management.

**CASE STUDY 2**: Customer dedicated facilities

A large, multinational pharmaceutical company required significant cost of goods reduction to deliver a market leading drug product. Dishman Carbogen Amcis Ltd optimized the process and built a dedicated facility for the API production. Dishman Carbogen Amcis Ltd further reduced costs by developing its own more cost-effective routes for the three key starting materials. An overall cost reduction of more than 50% was achieved. Routine commercial manufacture is now ongoing at the Bavla site, offering the customer significant cost advantages and a simplified and secure supply chain.

**CASE STUDY 3**: Commercialization from a Laboratory Process within 12 months

A European Specialty Pharmaceutical company approached Dishman Carbogen Amcis Ltd for the contract manufacture of a late-life cycle API. This client had a non-infringing laboratory scale process for the API which needed optimization and scale up to commercial production. The process was transferred and then optimized at an R&D level. This was followed by pilot scale validation batches and then 10mL commercial production within 9 months of initiating technology transfer.

During the commercial production, alternative, more cost effective supply solutions were found for key starting materials and these were incorporated into production post validation. An agreed regulatory programme was completed and Dishman Carbogen Amcis Ltd provided the client with a full technical dossier to enable regulatory filings. As a consequence of the success of this program, the client has transferred a further 3 projects into the Dishman Carbogen Amcis Group.
WHY IS DISHMAN CARBOGEN AMCIS LTD THE PARTNER FOR YOU?

**CUSTOMER SERVICE**
- A relationship-driven business model that invests in pharmaceutical companies rather than competes with them
- Transparency through open, responsive customer service and project management
- A continuum of services offered under flexible and innovative terms

**SECURITY OF SUPPLY**
- Technical and manufacturing excellence in multiple sites worldwide, allowing us to leverage the best in cost and quality controls
- We protect our customers' interests as if they were our own
- Strong, tenured leadership at corporate and local levels

**ADDING VALUE**
- Commitment to deliver excellent economical and technical services
- Offering the best of the New World as a centre for commerce
- Innovative development to competitive, long-term commercial supply

**CORPORATE SOCIAL RESPONSIBILITY**
We believe in making prosperity scalable through our social actions around education and healthcare. We remain committed to empowering communities and bringing meaningful positive change in their lives for an equitable and inclusive growth.

**EDUCATION**
We deeply understand that the advancement of our society and the progress of its members are inherently intertwined with education. Therefore, we consider it our duty to facilitate access to high-quality education and learning resources, particularly in areas and for individuals who have been unable to seize the opportunities available through mainstream channels.

**HEALTHCARE**
Our profound dedication lies in the pursuit of extending accessible and top-notch healthcare to all strata of society. Aligned with this objective, we have been actively involved in supporting hospitals and foundations to provide free medical aid to those in need. Through collaborative efforts, we have facilitated the implementation of a program enabling cost-free medical services, specifically paediatric heart surgeries, to young patients in need. Our partnerships reflect our continued support for healthcare initiatives, as we collectively strive to ensure comprehensive health services for the well-being of the community.

**QUATERNARY AMMONIUM SALTS EXPLAINED**
Quaternary Ammonium Salts (Quats) are a crucial part of organic chemistry processes across many major industries. But do you know exactly what Quats are, how and where they are used, and most importantly... why would you use them?